News

PipelineReview.com14d
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
SAN DIEGO, CA, USA & BERLIN, Germany I April 03, 2025 I Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a ...
Business Wire1mon
Alterome Doses First Patient in Phase 1 Study of ALTA3263, a Novel Pan-KRAS Dual ON/OFF Inhibitor, in Advanced Solid Tumors
SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a clinical-stage ... and preliminary clinical activity of ALTA3263 in adults with advanced unresectable or metastatic solid tumors with ...